"SI originally proposed that MSC's would repair damaged tissue (programmable stem cells were the "new paradigm" at the time which everyone was very excited about)"
this is a piont that i picked out for my interest too, Si was really wanting the Covid Ard trial to go the fully way with numbers, as there was so talk at some stage that OE might occur and the trail call off due to that positive outcome, he wanted to a followup at a 12 month point, to see if there was regeneration in the cohort, out of the near hour presentation post trial it is the main point I took out going into the future, I have a particular interest in "long covid" the true story of data still to come all around the world, heart, brain, other organs affected long term, remember many are still suffering with post infection symptoms 6 months or long after. I hope this 12 month revenue still occurs, there was advice to continue with the current number in the cohort. The trial was not stopped for safety issue, but rather the data outcome would not be reached. - patient treated with a different mix of treatment to what was decide when the design of the trial (a mistake). we ended up getting very sick patients pre treated with little chance given to helping them.... infection had already progress a piont too far. I wonder in NOV pull out early because of commercial outcomes, ..with so many more treatment out and still coming out post infection, would there be a commerical space for MSBs treatment? less likely to have access to patients. so if MSB finally gets approval then NOV has to fork out lots....but the return to that lots, might be minimal- MSB needs to get something across the line for its other platforms of treatment..
MSB Price at posting:
$1.37 Sentiment: Buy Disclosure: Held
(20min delay)